West Point Optical Group, LLC and Verséa Ophthalmics, Inc. Announce Partnership Supply Agreement for BIOVANCE®and BIOVANCE® 3L Ocular
Retrieved on:
Wednesday, April 3, 2024
BIOVANCE® and BIOVANCE® 3L Ocular, which are single-layer and three-layer (3L) allografts, respectively, are intended for use as a biological membrane covering that provides an extracellular matrix.
Key Points:
- BIOVANCE® and BIOVANCE® 3L Ocular, which are single-layer and three-layer (3L) allografts, respectively, are intended for use as a biological membrane covering that provides an extracellular matrix.
- BIOVANCE® 3L Ocular is acellular and consists of three layers of amniotic basement membrane that supports treatment of advanced ocular surface disease.
- As a barrier membrane, BIOVANCE® 3L Ocular is intended to protect the underlying tissue and preserve tissue plane boundaries.
- “We are excited to partner with Verséa Ophthalmics allowing our eye care professionals to deliver the benefits of BIOVANCE® and BIOVANCE® 3L Ocular products to their patients,” said John Womack, OD, West Point Optical Group’s Chief Medical Officer.